OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory eye diseases and ocular pain conditions. The company's lead candidate, urcosimod, is currently advancing through Phase II clinical trials for dry eye disease and neuropathic corneal pain, with preclinical development underway for allergic conjunctivitis and uveitis. The company is also developing OK-201, a separate therapeutic candidate targeting acute and chronic ocular pain.
As a development-stage enterprise, OKYO does not currently generate product revenue. The company's operations are concentrated in the United Kingdom, where it was incorporated in 2007 and remains headquartered in London. With four full-time employees, the company operates at a minimal scale typical of early-stage clinical-phase biotechnology firms. Its business model centers on advancing its pipeline candidates through clinical development stages, with commercialization potential dependent on successful trial outcomes and regulatory approval.
No 10-K filings found.